Relationship between RUNX1 and AXIN1 in ER-negative versus ER-positive Breast Cancer

References

• Chimge NO, Little GH, Baniwal SK, Adisetiyo H, Xie Y, Zhang T, O'Laughlin A, Liu ZY, Ulrich P, Martin A, et al. RUNX1 prevents oestrogen-mediated AXIN1 suppression and beta-catenin activation in ER-positive breast cancer. Nat Commun 2016; 7:10751; PMID:26916619; http://dx.doi.org/10.1038/ncomms10751
   PubMed Web of Science ®Google Scholar
• Pratap J, Lian JB, Stein GS. Metastatic bone disease: role of transcription factors and future targets. Bone 2011; 48:30-6; PMID: 20561908; http://dx.doi.org/10.1016/j.bone.2010.05.035
   PubMed Web of Science ®Google Scholar
• Cameron ER, Blyth K, Hanlon L, Kilbey A, Mackay N, Stewart M, Terry A, Vaillant F, Wotton S, Neil JC. The Runx genes as dominant oncogenes. Blood Cells Mol Dis 2003; 30:194-200; PMID:12732183; http://dx.doi.org/10.1016/S1079-9796(03)00031-7
   PubMedGoogle Scholar
• Ito Y, Bae SC, Chuang LS. The RUNX family: developmental regulators in cancer. Nat Rev Cancer 2015; 15:81-95; PMID:25592647; http://dx.doi.org/10.1038/nrc3877
   PubMed Web of Science ®Google Scholar
• Blyth K, Cameron ER, Neil JC. The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer 2005; 5:376-87; PMID:15864279; http://dx.doi.org/10.1038/nrc1607
   PubMed Web of Science ®Google Scholar
• Chimge NO, Frenkel B. The RUNX family in breast cancer: relationships with estrogen signaling. Oncogene 2013; 32:2121-30; PMID:23045283; http://dx.doi.org/10.1038/onc.2012.328
   PubMed Web of Science ®Google Scholar
• Ding Y, Harada Y, Imagawa J, Kimura A, Harada H. AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms. Blood 2009; 114:5201-5; PMID:19850737; http://dx.doi.org/10.1182/blood-2009-06-223982
   PubMed Web of Science ®Google Scholar
• Blyth K, Slater N, Hanlon L, Bell M, Mackay N, Stewart M, Neil JC, Cameron ER. Runx1 promotes B-cell survival and lymphoma development. Blood Cells Mol Dis 2009; 43:12-9; PMID:19269865; http://dx.doi.org/10.1016/j.bcmd.2009.01.013
   PubMed Web of Science ®Google Scholar
• Tang JL, Hou HA, Chen CY, Liu CY, Chou WC, Tseng MH, Huang CF, Lee FY, Liu MC, Yao M, et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood 2009; 114:5352-61; PMID:19808697; http://dx.doi.org/10.1182/blood-2009-05-223784
   PubMed Web of Science ®Google Scholar
• Mangan JK, Speck NA. RUNX1 Mutations in Clonal Myeloid Disorders: From Conventional Cytogenetics to Next Generation Sequencing, A Story 40 Years in the Making. Crit Rev Oncog 2011; 16:77-91; PMID:22150309; http://dx.doi.org/10.1615/CritRevOncog.v16.i1-2.80
   PubMedGoogle Scholar
• Silva FP, Morolli B, Storlazzi CT, Anelli L, Wessels H, Bezrookove V, Kluin-Nelemans HC, Giphart-Gassler M. Identification of RUNX1/AML1 as a classical tumor suppressor gene. Oncogene 2003; 22:538-47; PMID:12555067; http://dx.doi.org/10.1038/sj.onc.1206141
   PubMed Web of Science ®Google Scholar
• Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, Lawrence MS, Sivachenko AY, Sougnez C, Zou L, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012; 486:405-9; PMID:22722202; http://dx.doi.org/10.1038/nature11154
   PubMed Web of Science ®Google Scholar
• Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012; 486:353-60; PMID:22722193
   PubMed Web of Science ®Google Scholar
• TCGA. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490:61-70; PMID:23000897; http://dx.doi.org/10.1038/nature11412
   PubMed Web of Science ®Google Scholar
• van Bragt MP, Hu X, Xie Y, Li Z. RUNX1, a transcription factor mutated in breast cancer, controls the fate of ER-positive mammary luminal cells. Elife 2014; 4:e03881; PMID:25415051
   PubMedGoogle Scholar
• Lee E, Salic A, Kruger R, Heinrich R, Kirschner MW. The roles of APC and Axin derived from experimental and theoretical analysis of the Wnt pathway. PLoS Biol 2003; 1:E10; PMID:14551908; http://dx.doi.org/10.1371/journal.pbio.0000010
   PubMed Web of Science ®Google Scholar
• Li VS, Ng SS, Boersema PJ, Low TY, Karthaus WR, Gerlach JP, Mohammed S, Heck AJ, Maurice MM, Mahmoudi T, et al. Wnt signaling through inhibition of beta-catenin degradation in an intact Axin1 complex. Cell 2012; 149:1245-56; PMID:22682247; http://dx.doi.org/10.1016/j.cell.2012.05.002
   PubMed Web of Science ®Google Scholar
• Stamos JL, Weis WI. The beta-catenin destruction complex. Cold Spring Harb Perspect Biol 2013; 5:a007898; PMID:23169527; http://dx.doi.org/10.1101/cshperspect.a007898
   PubMed Web of Science ®Google Scholar
• Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127:469-80; PMID:17081971; http://dx.doi.org/10.1016/j.cell.2006.10.018
   PubMed Web of Science ®Google Scholar
• Rui Y, Xu Z, Lin S, Li Q, Rui H, Luo W, Zhou HM, Cheung PY, Wu Z, Ye Z, et al. Axin stimulates p53 functions by activation of HIPK2 kinase through multimeric complex formation. EMBO J 2004; 23:4583-94; PMID:15526030; http://dx.doi.org/10.1038/sj.emboj.7600475
   PubMed Web of Science ®Google Scholar
• Liu W, Rui H, Wang J, Lin S, He Y, Chen M, Li Q, Ye Z, Zhang S, Chan SC, et al. Axin is a scaffold protein in TGF-beta signaling that promotes degradation of Smad7 by Arkadia. EMBO J 2006; 25:1646-58; PMID:16601693; http://dx.doi.org/10.1038/sj.emboj.7601057
   PubMed Web of Science ®Google Scholar
• Arnold HK, Zhang X, Daniel CJ, Tibbitts D, Escamilla-Powers J, Farrell A, Tokarz S, Morgan C, Sears RC. The Axin1 scaffold protein promotes formation of a degradation complex for c-Myc. The EMBO journal 2009; 28:500-12; PMID:19131971; http://dx.doi.org/10.1038/emboj.2008.279
   PubMed Web of Science ®Google Scholar
• Zhang Y, Neo SY, Wang X, Han J, Lin SC. Axin forms a complex with MEKK1 and activates c-Jun NH(2)-terminal kinase/stress-activated protein kinase through domains distinct from Wnt signaling. J Biol Chem 1999; 274:35247-54; PMID:10575011; http://dx.doi.org/10.1074/jbc.274.49.35247
   PubMed Web of Science ®Google Scholar
• Azzolin L, Panciera T, Soligo S, Enzo E, Bicciato S, Dupont S, Bresolin S, Frasson C, Basso G, Guzzardo V, et al. YAP/TAZ incorporation in the beta-catenin destruction complex orchestrates the Wnt response. Cell 2014; 158:157-70; PMID:24976009; http://dx.doi.org/10.1016/j.cell.2014.06.013
   PubMed Web of Science ®Google Scholar
• Mazzoni SM, Fearon ER. AXIN1 and AXIN2 variants in gastrointestinal cancers. Cancer Lett 2014; 355:1-8; PMID:25236910; http://dx.doi.org/10.1016/j.canlet.2014.09.018
   PubMed Web of Science ®Google Scholar
• Salahshor S, Woodgett JR. The links between axin and carcinogenesis. J Clin Pathol 2005; 58:225-36; PMID:15735151; http://dx.doi.org/10.1136/jcp.2003.009506
   PubMed Web of Science ®Google Scholar
• Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T, Kawasoe T, Ishiguro H, Fujita M, Tokino T, et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 2000; 24:245-50; PMID:10700176; http://dx.doi.org/10.1038/73448
   PubMed Web of Science ®Google Scholar
• Takai A, Dang HT, Wang XW. Identification of drivers from cancer genome diversity in hepatocellular carcinoma. Int J Mol Sci 2014; 15:11142-60; PMID:24955791; http://dx.doi.org/10.3390/ijms150611142
   PubMed Web of Science ®Google Scholar
• Zhang X, Farrell AS, Daniel CJ, Arnold H, Scanlan C, Laraway BJ, Janghorban M, Lum L, Chen D, Troxell M, et al. Mechanistic insight into Myc stabilization in breast cancer involving aberrant Axin1 expression. Proc Natl Acad Sci U S A 2012; 109:2790-5; PMID:21808024; http://dx.doi.org/10.1073/pnas.1100764108
   PubMed Web of Science ®Google Scholar
• Cancer Facts & Figures. 2016. American Cancer Society, Inc.
   Google Scholar
• Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, Cronin KA. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 2014; 106; PMID:24777111; http://dx.doi.org/10.1093/jnci/dju055
   PubMedGoogle Scholar
• Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010; 11:1135-41; PMID:21087898; http://dx.doi.org/10.1016/S1470-2045(10)70257-6
   PubMed Web of Science ®Google Scholar
• Ignatiadis M, Sotiriou C. Luminal breast cancer: from biology to treatment. Nat Rev Clin Oncol 2013; 10:494-506; PMID:23881035; http://dx.doi.org/10.1038/nrclinonc.2013.124
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky AJ, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol 2014; 32:2255-69; PMID:24868023; http://dx.doi.org/10.1200/JCO.2013.54.2258
   PubMed Web of Science ®Google Scholar
• Croxtall JD, McKeage K. Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women. Drugs 2011; 71:363-80; PMID:21319872; http://dx.doi.org/10.2165/11204810-000000000-00000
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thurlimann B, Paridaens R, Smith I, Mauriac L, Forbes J, Price KN, Regan MM, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009; 361:766-76; PMID:19692688; http://dx.doi.org/10.1056/NEJMoa0810818
   PubMed Web of Science ®Google Scholar
• Hudis CA. Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med 2007; 357:39-51; PMID:17611206; http://dx.doi.org/10.1056/NEJMra043186
   PubMed Web of Science ®Google Scholar
• Higa GM, Abraham J. Lapatinib in the treatment of breast cancer. Expert Rev Anticancer Ther 2007; 7:1183-92; PMID:17892419; http://dx.doi.org/10.1586/14737140.7.9.1183
   PubMed Web of Science ®Google Scholar
• Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Arch Gynecol Obstet 2016; 293:247-69; PMID:26341644; http://dx.doi.org/10.1007/s00404-015-3859-y
   PubMed Web of Science ®Google Scholar
• Palma G, Frasci G, Chirico A, Esposito E, Siani C, Saturnino C, Arra C, Ciliberto G, Giordano A, D'Aiuto M. Triple negative breast cancer: looking for the missing link between biology and treatments. Oncotarget 2015; 6:26560-74; PMID:26387133; http://dx.doi.org/10.18632/oncotarget.5306
   PubMed Web of Science ®Google Scholar
• Kalimutho M, Parsons K, Mittal D, Lopez JA, Srihari S, Khanna KK. Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease. Trends Pharmacol Sci 2015; 36:822-46; PMID:26538316; http://dx.doi.org/10.1016/j.tips.2015.08.009
   PubMed Web of Science ®Google Scholar
• den Hollander P, Savage MI, Brown PH. Targeted therapy for breast cancer prevention. Front Oncol 2013; 3:250; PMID:24069582; http://dx.doi.org/10.3389/fonc.2013.00250
   PubMedGoogle Scholar
• Little GH, Baniwal SK, Adisetiyo H, Groshen S, Chimge NO, Kim SY, Khalid O, Hawes D, Jones JO, Pinski J, et al. Differential Effects of RUNX2 on the Androgen Receptor in Prostate Cancer: Synergistic Stimulation of a Gene Set Exemplified by SNAI2 and Subsequent Invasiveness. Cancer Res 2014; 74:2857-68; PMID:24648349; http://dx.doi.org/10.1158/0008-5472.CAN-13-2003
   PubMed Web of Science ®Google Scholar
• Baniwal SK, Khalid O, Sir D, Buchanan G, Coetzee GA, Frenkel B. Repression of Runx2 by androgen receptor (AR) in osteoblasts and prostate cancer cells: AR binds Runx2 and abrogates its recruitment to DNA. Mol Endocrinol 2009; 23:1203-14; PMID:19389811; http://dx.doi.org/10.1210/me.2008-0470
   PubMed Web of Science ®Google Scholar
• Khalid O, Baniwal SK, Purcell DJ, Leclerc N, Gabet Y, Stallcup MR, Coetzee GA, Frenkel B. Modulation of Runx2 activity by estrogen receptor-alpha: implications for osteoporosis and breast cancer. Endocrinology 2008; 149:5984-95; PMID:18755791; http://dx.doi.org/10.1210/en.2008-0680
   PubMed Web of Science ®Google Scholar
• Kawate H, Wu Y, Ohnaka K, Takayanagi R. Mutual transactivational repression of Runx2 and the androgen receptor by an impairment of their normal compartmentalization. J Steroid Biochem Mol Biol 2007; 105:46-56; PMID:17627815; http://dx.doi.org/10.1016/j.jsbmb.2006.11.020
   PubMed Web of Science ®Google Scholar
• Takayama K, Suzuki T, Tsutsumi S, Fujimura T, Urano T, Takahashi S, Homma Y, Aburatani H, Inoue S. RUNX1, an androgen- and EZH2-regulated gene, has differential roles in AR-dependent and -independent prostate cancer. Oncotarget 2015; 6:2263-76; PMID:25537508; http://dx.doi.org/10.18632/oncotarget.2949
   PubMed Web of Science ®Google Scholar
• Huang B, Qu Z, Ong CW, Tsang YH, Xiao G, Shapiro D, Salto-Tellez M, Ito K, Ito Y, Chen LF. RUNX3 acts as a tumor suppressor in breast cancer by targeting estrogen receptor alpha. Oncogene 2012; 31:527-34; PMID:21706051; http://dx.doi.org/10.1038/onc.2011.252
   PubMed Web of Science ®Google Scholar
• Chimge NO, Baniwal SK, Luo J, Coetzee S, Khalid O, Berman BP, Tripathy D, Ellis MJ, Frenkel B. Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness. Clin Cancer Res 2012; 18:901-11; PMID:22147940; http://dx.doi.org/10.1158/1078-0432.CCR-11-1530
   PubMed Web of Science ®Google Scholar
• Chimge NO, Baniwal SK, Little GH, Chen YB, Kahn M, Tripathy D, Borok Z, Frenkel B. Regulation of breast cancer metastasis by Runx2 and estrogen signaling: the role of SNAI2. Breast Cancer Res 2011; 13:R127; PMID:22151997; http://dx.doi.org/10.1186/bcr3073
   PubMedGoogle Scholar
• Browne G, Dragon JA, Hong D, Messier TL, Gordon JA, Farina NH, Boyd JR, VanOudenhove JJ, Perez AW, Zaidi SK, et al. MicroRNA-378-mediated suppression of Runx1 alleviates the aggressive phenotype of triple-negative MDA-MB-231 human breast cancer cells. Tumour Biol 2016; PMID:26749280
   PubMed Web of Science ®Google Scholar
• Browne G, Taipaleenmaki H, Bishop NM, Madasu SC, Shaw LM, van Wijnen AJ, Stein JL, Stein GS, Lian JB. Runx1 is associated with breast cancer progression in MMTV-PyMT transgenic mice and its depletion in vitro inhibits migration and invasion. J Cell Physiol 2015; 230:2522-32; PMID:25802202; http://dx.doi.org/10.1002/jcp.24989
   PubMed Web of Science ®Google Scholar
• Ferrari N, Mohammed ZM, Nixon C, Mason SM, Mallon E, McMillan DC, Morris JS, Cameron ER, Edwards J, Blyth K. Expression of RUNX1 correlates with poor patient prognosis in triple negative breast cancer. PLoS One 2014; 9:e100759; PMID:24967588; http://dx.doi.org/10.1371/journal.pone.0100759
   PubMed Web of Science ®Google Scholar
• Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, van Wijnen AJ, Stein JL, Languino LR, Altieri DC, et al. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 2010; 29:811-21; PMID:19915614; http://dx.doi.org/10.1038/onc.2009.389
   PubMed Web of Science ®Google Scholar
• Blyth K, Vaillant F, Jenkins A, McDonald L, Pringle MA, Huser C, Stein T, Neil J, Cameron ER. Runx2 in normal tissues and cancer cells: A developing story. Blood cells, molecules & diseases 2010; 45:117-23; PMID:20580290; http://dx.doi.org/10.1016/j.bcmd.2010.05.007
   PubMed Web of Science ®Google Scholar
• Baniwal SK, Khalid O, Gabet Y, Shah RR, Purcell DJ, Mav D, Kohn-Gabet AE, Shi Y, Coetzee GA, Frenkel B. Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis. Mol Cancer 2010; 9:258; PMID:20863401; http://dx.doi.org/10.1186/1476-4598-9-258
   PubMed Web of Science ®Google Scholar
• Boregowda RK, Medina DJ, Markert E, Bryan MA, Chen W, Chen S, Rabkin A, Vido MJ, Gunderson SI, Chekmareva M, et al. The transcription factor RUNX2 regulates receptor tyrosine kinase expression in melanoma. Oncotarget 2016; PMID:27102439
   PubMed Web of Science ®Google Scholar
• Guo ZJ, Yang L, Qian F, Wang YX, Yu X, Ji CD, Cui W, Xiang DF, Zhang X, Zhang P, et al. Transcription factor RUNX2 up-regulates chemokine receptor CXCR4 to promote invasive and metastatic potentials of human gastric cancer. Oncotarget 2016; 7:20999-1012; PMID:27007162
   PubMed Web of Science ®Google Scholar
• Li XQ, Lu JT, Tan CC, Wang QS, Feng YM. RUNX2 promotes breast cancer bone metastasis by increasing integrin alpha5-mediated colonization. Cancer Lett 2016; 380:78-86; PMID:27317874; http://dx.doi.org/10.1016/j.canlet.2016.06.007
   PubMed Web of Science ®Google Scholar
• Shin MH, He Y, Marrogi E, Piperdi S, Ren L, Khanna C, Gorlick R, Liu C, Huang J. A RUNX2-Mediated Epigenetic Regulation of the Survival of p53 Defective Cancer Cells. PLoS Genet 2016; 12:e1005884; PMID:26925584; http://dx.doi.org/10.1371/journal.pgen.1005884
   PubMedGoogle Scholar
• Tandon M, Chen Z, Othman AH, Pratap J. Role of Runx2 in IGF-1Rbeta/Akt- and AMPK/Erk-dependent growth, survival and sensitivity towards metformin in breast cancer bone metastasis. Oncogene 2016; PMID:26804175
   PubMed Web of Science ®Google Scholar
• Wysokinski D, Blasiak J, Pawlowska E. Role of RUNX2 in Breast Carcinogenesis. Int J Mol Sci 2015; 16:20969-93; PMID:26404249; http://dx.doi.org/10.3390/ijms160920969
   PubMed Web of Science ®Google Scholar